Advances in Immunotherapy
Harnessing Immunity to Overcome Cancer and Restore Immune Tolerance
5/11/2027 - May 12, 2027 ALL TIMES EDT
Cambridge Healthtech Institute’s 12th Annual Advances in Immunotherapy conference explores the latest breakthroughs shaping the future of immunotherapy across oncology, autoimmune disease, and other immune-mediated disorders. Key topics include overcoming resistance, targeting the TME, identifying new targets such as Dark Antigens, and mechanisms for anticancer immunity. The program will also examine the engineering of safer, more effective cell therapies and immune cell engagers for treating solid tumors and autoimmune disease. Presentations will span both adoptive and innate immune approaches, encompassing immune-based therapies, protein therapeutics, and other emerging immunotherapy platforms.
Preliminary Agenda

PLENARY KEYNOTE SESSION

Panel Moderator:

PANEL DISCUSSION: From Mechanism to Modality: Smarter Drug Design in Autoimmunity

Yang Shen, PhD, Executive Director, Antibody Engineering, Bispecifics, Regeneron , Vice President , Bispecifics & Antibody Engineering , Regeneron

Panelists:

Stephen J. Demarest, PhD, CSO, Tentarix Biotherapeutics , CSO , Tentarix

Ryan P. Larson, PhD, Vice President & Head, Translational Sciences, Umoja Biopharma , SVP & Head , Translational Sciences , Umoja Biopharma

Kira Rubtsova, PhD, Associate Vice President, Eli Lilly and Company , Dir , Eli Lilly & Co

Qizhi Tang, PhD, Professor in Residence, Surgery, University of California San Francisco , Prof in Residence , Surgery , Univ of California San Francisco

TCRS and DARK ANTIGENS: OVERCOMING RESISTANCE AND LIMITATIONS IN IMMUNOTHERAPY

KEYNOTE PRESENTATION:
Bright Side of The Dark Genome: Antigens for Next-Generation Cancer Vaccines

Photo of Bernard A. Fox, PhD, Member & Harder Family Endowed Chair in Cancer Research, Molecular and Tumor Immunology Laboratory, Earle A. Chiles Research Institute, Providence Cancer Institute , Endowed Chair Cancer Research & Chief , Molecular & Tumor Immunology , Providence Cancer Institute
Bernard A. Fox, PhD, Member & Harder Family Endowed Chair in Cancer Research, Molecular and Tumor Immunology Laboratory, Earle A. Chiles Research Institute, Providence Cancer Institute , Endowed Chair Cancer Research & Chief , Molecular & Tumor Immunology , Providence Cancer Institute

Expanding the Reach of Immunotherapy: Clinical Progress with PRAME-Directed TCR T Cell Therapies and Bispecifics

Photo of Cedrik M. Britten, CMO, Immatics Biotechnologies GmbH , CMO , Immatics Biotechnologies GmbH
Cedrik M. Britten, CMO, Immatics Biotechnologies GmbH , CMO , Immatics Biotechnologies GmbH

Targeting HLA-presented peptides expands immunotherapy beyond cell surface antigens. This presentation highlights clinical progress targeting PRAME, a cancer-associated antigen expressed in over 50 cancers, with the TCR T cell therapies anzutresgene autoleucel (anzu-cel; IMA203) and IMA203CD8, and the TCR bispecific IMA402 in advanced solid tumors. Emerging data suggest encouraging antitumor activity with a manageable safety profile. Translational insights inform opportunities to investigate these approaches across indications, treatment settings, and combinations.

Two Development Candidate TCR Engagers Against the Densest pHLA Targets in Solid Tumours

Photo of Sarah Leonard, PhD, CEO, T-Cypher Bio , CEO , T-Cypher Bio
Sarah Leonard, PhD, CEO, T-Cypher Bio , CEO , T-Cypher Bio

Most peptide:HLA tumour targets are too scarce to kill tumours robustly or sustain a durable response. Our novel targets are presented at 5-25 fold the copy number of PRAME in multiple solid tumours. Our half-life-extended TCEs lyse patient-derived tumour cells with no detectable cytokine release to 100 nM and drive potent tumour killing in vivo.

Immunopeptidomics-Guided TCR Discovery for Pancreatic Cancer

Photo of William Freed-Pastor, MD, PhD, Assistant Professor, Medicine, Harvard Medical School , Assistant Professor , Medicine , Dana-Farber Cancer Institute
William Freed-Pastor, MD, PhD, Assistant Professor, Medicine, Harvard Medical School , Assistant Professor , Medicine , Dana-Farber Cancer Institute

Mounting evidence now supports that the targetable antigen landscape in cancer is considerably broader than previously appreciated. Beyond somatic mutations or canonical tumor-associated antigens, cryptic antigens derived from noncanonical open reading frames, dysregulated expression of transposable elements, aberrant splicing, and mistranslation variants have been empirically detected across a range of solid tumors and hematologic malignancies. In this talk, we will cover methods for cryptic antigen detection, review approaches to assess tumor selectivity, and discuss therapeutic strategies for this emerging antigenic class.

High-Throughput TCR–Epitope Mapping with RNA-Barcoded Peptide-MHC Display Vesicles

Photo of James Asaki, PhD Student, Marson Lab, University of California, San Francisco , PhD Student , University of California, San Francisco (UCSF)
James Asaki, PhD Student, Marson Lab, University of California, San Francisco , PhD Student , University of California, San Francisco (UCSF)


Systematically pairing peptide–MHCs (pMHCs) with cognate T cell receptors (TCRs) at scale remains challeng. We describe StarTrack, a high-throughput workflow that maps large libraries of pooled pMHCs to cognate TCRs. Our platform utilizes pooled libraries of RNA-barcoded pMHC display vesicles to label antigen-specific T cells, linking pMHC identity with TCR sequence and transcriptional state. We applied StarTrack to identify anti-viral CD8 T cell reactivities in healthy donors, profile responses to HIV vaccination, map tumor-infiltrating lymphocyte (TIL) reactivities, and characterize binding rules for computationally designed pMHC binders. StarTrack enables scalable, systematic epitope discovery, immune monitoring, and therapeutic receptor engineering.

ADVANCES IN IMMUNOCYTOKINES

Synthetic Cytokines for Cancer Immunotherapy

Photo of Stephanie K. Dougan, PhD, Associate Professor, Cancer Immunology and Virology, Dana Farber Cancer Institute , Associate Professor , Cancer Immunology and Virology , Dana Farber Cancer Institute
Stephanie K. Dougan, PhD, Associate Professor, Cancer Immunology and Virology, Dana Farber Cancer Institute , Associate Professor , Cancer Immunology and Virology , Dana Farber Cancer Institute

Cytokines can have powerful anti-tumor activity, but their therapeutic use is hampered by systemic toxicity and limited efficacy. Advances in protein design offer opportunities to reimagine cytokine-based therapies. Here we report a designed mimic of IL-21 whose enhanced stability confers enhanced biological activity across multiple cancer models including melanoma and pancreatic cancer. Ongoing efforts to generate tumor-targeted, conditionally activatable cytokines will further expand the therapeutic window for synthetic cytokines.

Update on PEC3001, a Next-Generation PD-1-IL-2 Immunocytokine

Photo of Jack Huck, PhD, Senior Scientist, Protein Sciences, PharmaEssentia Corp. , Senior Scientist , Protein Sciences , PharmaEssentia Corp
Jack Huck, PhD, Senior Scientist, Protein Sciences, PharmaEssentia Corp. , Senior Scientist , Protein Sciences , PharmaEssentia Corp

PEC3001 is a PD-1–targeted IL-2 immunocytokine that retains IL-2Ra binding to preferentially activate tumor-specific T cells. In preclinical studies, it selectively stimulated activated T cells with minimal naïve T cell and NK-cell activation. A mouse surrogate demonstrated superior anti-tumor efficacy versus comparator treatments, durable tumor regression, immune memory, and favorable tolerability. In patient-derived tumors studied ex vivo, PEC3001 enhanced inflammatory cytokine production and cytotoxic gene expression with minimal Treg-associated signatures. These findings support clinical development, with a first-in-human trial in advanced solid tumors expected to begin in late 2026.

IMMUNE-CELL ENGAGERS, INNATE IMMUNITY, CAR TREGS

Advancing Gamma-Delta T Cell Engagers as an Alternative to CD3 Targeting

Photo of Oxana Polyakova, PhD, Senior Vice President, R&D, IN8bio Inc. , SVP , R&D , IN8bio Inc
Oxana Polyakova, PhD, Senior Vice President, R&D, IN8bio Inc. , SVP , R&D , IN8bio Inc

INB-619 is a CD19-directed, pan-?d T cell engager built around a gamma-delta expansion domain (GDED): a TCR-binding module that activates and expands Vd1, Vd2, and Vd3 rather than a single subset. Picomolar cytotoxicity, ?d expansion from <2% to >50% of culture, minimal CRS cytokine release, and dose-dependent tumor reduction in NSG xenografts support a wider window than CD3 engagers.

Engaging Gamma-Delta T Cells in Both Blood and Tumor with CYT X300

Photo of James W. Legg, PhD, CSO, Cytospire Therapeutics Ltd. , CSO , Cytospire Therapeutics Ltd
James W. Legg, PhD, CSO, Cytospire Therapeutics Ltd. , CSO , Cytospire Therapeutics Ltd

T cell engagers are an emerging immunotherapeutic modality in solid tumors, however, successful application has been limited by toxicity and paucity of suitable tumor associated antigens (TAAs). Cytospire has developed CYT X300, a pan-?d engager that targets EGFR positive solid tumors and activates all subsets of ?dT cells. CYT X300 induces robust proliferation and tumor cell killing and is well tolerated in NHP at high doses.

CAR Tregs as Therapy for Neurodegenerative Diseases

Photo of Charles L Sentman, PhD, Professor and Director, Center for Synthetic Immunity, Microbiology & Immunology, Dartmouth College , Prof & Dir Ctr for Synthetic Immunity , Microbiology & Immunology , Dartmouth College
Charles L Sentman, PhD, Professor and Director, Center for Synthetic Immunity, Microbiology & Immunology, Dartmouth College , Prof & Dir Ctr for Synthetic Immunity , Microbiology & Immunology , Dartmouth College

We have developed CAR Tregs as a means to deliver targeted anti-inflammatory and neuroprotective proteins into the CNS to treat ALS and Alzheimer’s disease. These CAR Tregs expand to clinical scale while maintaining a robust Treg phenotype. The CARs are targeted to disease-associated aggregated proteins, and using humanized disease models, we show human CAR Treg presence within the CNS, reduced neuroinflammation, and reductions in disease associated biomarkers.

IMMUNOTHERAPIES FOR AUTOIMMUNE AND I&I

Immunotherapies for Antigen-Specific Tolerance

Photo of Christopher M. Jewell, PhD, Institute Professor, Translational Engineering, Robert E. Fischell Institute for Biomedical Devices, University of Maryland , Institute Professor , University of Maryland
Christopher M. Jewell, PhD, Institute Professor, Translational Engineering, Robert E. Fischell Institute for Biomedical Devices, University of Maryland , Institute Professor , University of Maryland

While CAR T-cell therapies can broadly deplete target cell populations, antigen-specific approaches aim to selectively suppress disease-driving immune responses while preserving protective immunity. This presentation will explore emerging immunotherapies designed to induce antigen-specific tolerance, highlighting their potential to offer more precise treatment for autoimmune disease. Discussion will consider therapeutic strategies, opportunities for durable immune modulation, and challenges in translating these approaches into clinical practice across a range of disease settings.

Programming Dendritic Cells in vivo with Multispecific Cytokine Engagers to Direct T Cell Stemness, Immunity, and Tolerance

Photo of Daniel Hawiger, MD, PhD, Professor, Department of Molecular Microbiology & Immunology, Saint Louis University, School of Medicine , Professor , Department of Molecular Microbiology & Immunology , Saint Louis University, School of Medicine
Daniel Hawiger, MD, PhD, Professor, Department of Molecular Microbiology & Immunology, Saint Louis University, School of Medicine , Professor , Department of Molecular Microbiology & Immunology , Saint Louis University, School of Medicine

Dendritic cells integrate signals to balance tolerance and immunity whereas stem-like T cells critically orchestrate a long-term development of immune responses. By employing potent and highly specific novel recombinant biologics that target dendritic cells, we induce defined maturation states of dendritic cells that present specific antigens to T cells to result in a precise generation of desired immune responses. Our findings are directly relevant for tumor and autoimmunity immunotherapies.

Precision Immunotherapies for Autoimmune Disease: Emerging Approaches in T Cell Engagers and Cellular Therapies

Photo of Maximilian F. Konig, MD, Assistant Professor, Medicine, Cellular Therapy Program, Johns Hopkins University School of Medicine , Director, Cellular Therapy Program (Autoimmunity) , Medicine, Cellular Therapy Program , The Johns Hopkins University School of Medicine
Maximilian F. Konig, MD, Assistant Professor, Medicine, Cellular Therapy Program, Johns Hopkins University School of Medicine , Director, Cellular Therapy Program (Autoimmunity) , Medicine, Cellular Therapy Program , The Johns Hopkins University School of Medicine

Broad immune-cell depletion can induce deep and durable responses in autoimmune disease but comes at the cost of protective immunity and excess toxicities. This talk will review emerging precision immunotherapy modalities to selectively deplete pathogenic B cells or T cells. Chimeric autoantigen T cell receptor (CATCR)-T cells will be highlighted for antigen-specific targeting of autoreactive B cells, alongside IGHV4-34-directed T cells for clonotypic targeting in lupus and B cell lymphoma. TRBV×CD3 T cell engagers will illustrate repertoire-directed targeting of pathogenic T cells in HLA-B27-associated autoimmune diseases, advancing immune effector therapies toward greater specificity and reduced collateral immune depletion.

CAR-MSC Technology for Autoimmune Disease

Photo of Saad Kenderian, PhD, Assistant Professor, Medicine and Oncology, Mayo Clinic College of Medicine; Co-Leader, Cancer Immunology Immunotherapy, Mayo Clinic Cancer Center , Asst Prof of Medicine & Oncology & Sr Consultant , Hematology & Bone Marrow Transplantation , Mayo Clinic
Saad Kenderian, PhD, Assistant Professor, Medicine and Oncology, Mayo Clinic College of Medicine; Co-Leader, Cancer Immunology Immunotherapy, Mayo Clinic Cancer Center , Asst Prof of Medicine & Oncology & Sr Consultant , Hematology & Bone Marrow Transplantation , Mayo Clinic

For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute
Phone: +44 7837 651 303
Email: [email protected]

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: +1 781-972-5452
Email: [email protected]

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: +1 781-972-1340
Email: [email protected]


Register

View By:


Premier Sponsors

Biointron_new       Kactus